Compile Data Set for Download or QSAR
Report error Found 400 Enz. Inhib. hit(s) with all data for entry = 2493
TargetEpidermal growth factor receptor [T790M](Human)
Ariad Pharmaceuticals

US Patent
LigandPNGBDBM368410(N-(5-((5-chloro-4-(1-methyl-1,6,7,8-tetrahydrocycl...)
Affinity DataIC50: 100nMAssay Description:A compound's ability in selectively inhibiting EGFR exon 19 deletion and T790M concurrent mutations can be assessed using Ba/F3 cells, a murine p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetEpidermal growth factor receptor(Human)
Ariad Pharmaceuticals

US Patent
LigandPNGBDBM368410(N-(5-((5-chloro-4-(1-methyl-1,6,7,8-tetrahydrocycl...)
Affinity DataIC50: 100nMAssay Description:A compound's ability in selectively inhibiting EGFR exon 20 insertion mutations can be assessed using Ba/F3 cells, a murine pro-B cell line, whic...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetEpidermal growth factor receptor(Human)
Ariad Pharmaceuticals

US Patent
LigandPNGBDBM368416(US10227342, Example 48)
Affinity DataIC50: 100nMAssay Description:A compound's ability in selectively inhibiting EGFR exon 20 insertion mutations can be assessed using Ba/F3 cells, a murine pro-B cell line, whic...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetEpidermal growth factor receptor [T790M](Human)
Ariad Pharmaceuticals

US Patent
LigandPNGBDBM368415(US10227342, Example 47)
Affinity DataIC50: 100nMAssay Description:A compound's ability in selectively inhibiting EGFR exon 19 deletion and T790M concurrent mutations can be assessed using Ba/F3 cells, a murine p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetEpidermal growth factor receptor [T790M](Human)
Ariad Pharmaceuticals

US Patent
LigandPNGBDBM368417(US10227342, Example 49)
Affinity DataIC50: 100nMAssay Description:A compound's ability in selectively inhibiting EGFR exon 19 deletion and T790M concurrent mutations can be assessed using Ba/F3 cells, a murine p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetEpidermal growth factor receptor [T790M](Human)
Ariad Pharmaceuticals

US Patent
LigandPNGBDBM368416(US10227342, Example 48)
Affinity DataIC50: 100nMAssay Description:A compound's ability in selectively inhibiting EGFR exon 19 deletion and T790M concurrent mutations can be assessed using Ba/F3 cells, a murine p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetEpidermal growth factor receptor [T790M](Human)
Ariad Pharmaceuticals

US Patent
LigandPNGBDBM368412(US10227342, Example 45)
Affinity DataIC50: 100nMAssay Description:A compound's ability in selectively inhibiting EGFR exon 19 deletion and T790M concurrent mutations can be assessed using Ba/F3 cells, a murine p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetEpidermal growth factor receptor [T790M](Human)
Ariad Pharmaceuticals

US Patent
LigandPNGBDBM368411(US10227342, Example 44)
Affinity DataIC50: 100nMAssay Description:A compound's ability in selectively inhibiting EGFR exon 19 deletion and T790M concurrent mutations can be assessed using Ba/F3 cells, a murine p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetEpidermal growth factor receptor [T790M](Human)
Ariad Pharmaceuticals

US Patent
LigandPNGBDBM368414(US10227342, Example 46)
Affinity DataIC50: 100nMAssay Description:A compound's ability in selectively inhibiting EGFR exon 19 deletion and T790M concurrent mutations can be assessed using Ba/F3 cells, a murine p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetEpidermal growth factor receptor [T790M,L858R](Human)
Ariad Pharmaceuticals

US Patent
LigandPNGBDBM50029685(CHEMBL3353404 | US10227342, Example 52)
Affinity DataIC50: 100nMAssay Description:A compound's ability in selectively inhibiting EGFR L858R and T790M concurrent mutations can be assessed using Ba/F3 cells, a murine pro-B cell l...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetEpidermal growth factor receptor [T790M](Human)
Ariad Pharmaceuticals

US Patent
LigandPNGBDBM50029685(CHEMBL3353404 | US10227342, Example 52)
Affinity DataIC50: 100nMAssay Description:A compound's ability in selectively inhibiting EGFR exon 19 deletion and T790M concurrent mutations can be assessed using Ba/F3 cells, a murine p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetEpidermal growth factor receptor(Human)
Ariad Pharmaceuticals

US Patent
LigandPNGBDBM50029685(CHEMBL3353404 | US10227342, Example 52)
Affinity DataIC50: 100nMAssay Description:A compound's ability in selectively inhibiting EGFR exon 20 insertion mutations can be assessed using Ba/F3 cells, a murine pro-B cell line, whic...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetEpidermal growth factor receptor(Human)
Ariad Pharmaceuticals

US Patent
LigandPNGBDBM50029685(CHEMBL3353404 | US10227342, Example 52)
Affinity DataIC50: 100nMAssay Description:A compound's ability in selectively inhibiting EGFR exon 20 insertion mutations can be assessed using Ba/F3 cells, a murine pro-B cell line, whic...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetEpidermal growth factor receptor [T790M](Human)
Ariad Pharmaceuticals

US Patent
LigandPNGBDBM368421(US10227342, Example 53)
Affinity DataIC50: 100nMAssay Description:A compound's ability in selectively inhibiting EGFR exon 19 deletion and T790M concurrent mutations can be assessed using Ba/F3 cells, a murine p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetEpidermal growth factor receptor [T790M](Human)
Ariad Pharmaceuticals

US Patent
LigandPNGBDBM368418(US10227342, Example 50)
Affinity DataIC50: 100nMAssay Description:A compound's ability in selectively inhibiting EGFR exon 19 deletion and T790M concurrent mutations can be assessed using Ba/F3 cells, a murine p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetEpidermal growth factor receptor [T790M](Human)
Ariad Pharmaceuticals

US Patent
LigandPNGBDBM368419(US10227342, Example 51)
Affinity DataIC50: 100nMAssay Description:A compound's ability in selectively inhibiting EGFR exon 19 deletion and T790M concurrent mutations can be assessed using Ba/F3 cells, a murine p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetEpidermal growth factor receptor(Human)
Ariad Pharmaceuticals

US Patent
LigandPNGBDBM368419(US10227342, Example 51)
Affinity DataIC50: 100nMAssay Description:A compound's ability in selectively inhibiting EGFR exon 20 insertion mutations can be assessed using Ba/F3 cells, a murine pro-B cell line, whic...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetEpidermal growth factor receptor(Human)
Ariad Pharmaceuticals

US Patent
LigandPNGBDBM50029664(CHEMBL3353408 | US10227342, Example 56)
Affinity DataIC50: 100nMAssay Description:A compound's ability in selectively inhibiting Her2 exon 20 YVMA insertion mutations can be assessed using Ba/F3 cells, a murine pro-B cell line,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetEpidermal growth factor receptor [T790M,L858R](Human)
Ariad Pharmaceuticals

US Patent
LigandPNGBDBM50029664(CHEMBL3353408 | US10227342, Example 56)
Affinity DataIC50: 100nMAssay Description:A compound's ability in selectively inhibiting EGFR L858R and T790M concurrent mutations can be assessed using Ba/F3 cells, a murine pro-B cell l...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetEpidermal growth factor receptor [T790M](Human)
Ariad Pharmaceuticals

US Patent
LigandPNGBDBM50029664(CHEMBL3353408 | US10227342, Example 56)
Affinity DataIC50: 100nMAssay Description:A compound's ability in selectively inhibiting EGFR exon 19 deletion and T790M concurrent mutations can be assessed using Ba/F3 cells, a murine p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetEpidermal growth factor receptor(Human)
Ariad Pharmaceuticals

US Patent
LigandPNGBDBM50029664(CHEMBL3353408 | US10227342, Example 56)
Affinity DataIC50: 100nMAssay Description:A compound's ability in selectively inhibiting EGFR exon 20 insertion mutations can be assessed using Ba/F3 cells, a murine pro-B cell line, whic...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetEpidermal growth factor receptor [T790M,L858R](Human)
Ariad Pharmaceuticals

US Patent
LigandPNGBDBM50029687(CHEMBL3353412 | US10227342, Example 57)
Affinity DataIC50: 100nMAssay Description:A compound's ability in selectively inhibiting EGFR L858R and T790M concurrent mutations can be assessed using Ba/F3 cells, a murine pro-B cell l...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetEpidermal growth factor receptor [T790M](Human)
Ariad Pharmaceuticals

US Patent
LigandPNGBDBM50029687(CHEMBL3353412 | US10227342, Example 57)
Affinity DataIC50: 100nMAssay Description:A compound's ability in selectively inhibiting EGFR exon 19 deletion and T790M concurrent mutations can be assessed using Ba/F3 cells, a murine p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetEpidermal growth factor receptor(Human)
Ariad Pharmaceuticals

US Patent
LigandPNGBDBM50029687(CHEMBL3353412 | US10227342, Example 57)
Affinity DataIC50: 100nMAssay Description:A compound's ability in selectively inhibiting EGFR exon 20 insertion mutations can be assessed using Ba/F3 cells, a murine pro-B cell line, whic...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetEpidermal growth factor receptor [T790M](Human)
Ariad Pharmaceuticals

US Patent
LigandPNGBDBM368422(US10227342, Example 54)
Affinity DataIC50: 100nMAssay Description:A compound's ability in selectively inhibiting EGFR exon 19 deletion and T790M concurrent mutations can be assessed using Ba/F3 cells, a murine p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetEpidermal growth factor receptor(Human)
Ariad Pharmaceuticals

US Patent
LigandPNGBDBM50029664(CHEMBL3353408 | US10227342, Example 56)
Affinity DataIC50: 100nMAssay Description:A compound's ability in selectively inhibiting EGFR exon 20 insertion mutations can be assessed using Ba/F3 cells, a murine pro-B cell line, whic...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetEpidermal growth factor receptor [T790M](Human)
Ariad Pharmaceuticals

US Patent
LigandPNGBDBM368423(US10227342, Example 55)
Affinity DataIC50: 100nMAssay Description:A compound's ability in selectively inhibiting EGFR exon 19 deletion and T790M concurrent mutations can be assessed using Ba/F3 cells, a murine p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetEpidermal growth factor receptor(Human)
Ariad Pharmaceuticals

US Patent
LigandPNGBDBM368428(US10227342, Example 60)
Affinity DataIC50: 100nMAssay Description:A compound's ability in selectively inhibiting EGFR exon 20 insertion mutations can be assessed using Ba/F3 cells, a murine pro-B cell line, whic...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetEpidermal growth factor receptor(Human)
Ariad Pharmaceuticals

US Patent
LigandPNGBDBM368428(US10227342, Example 60)
Affinity DataIC50: 100nMAssay Description:A compound's ability in selectively inhibiting EGFR exon 20 insertion mutations can be assessed using Ba/F3 cells, a murine pro-B cell line, whic...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetEpidermal growth factor receptor(Human)
Ariad Pharmaceuticals

US Patent
LigandPNGBDBM368427(US10227342, Example 59)
Affinity DataIC50: 100nMAssay Description:A compound's ability in selectively inhibiting Her2 exon 20 YVMA insertion mutations can be assessed using Ba/F3 cells, a murine pro-B cell line,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetEpidermal growth factor receptor [T790M](Human)
Ariad Pharmaceuticals

US Patent
LigandPNGBDBM368427(US10227342, Example 59)
Affinity DataIC50: 100nMAssay Description:A compound's ability in selectively inhibiting EGFR exon 19 deletion and T790M concurrent mutations can be assessed using Ba/F3 cells, a murine p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetEpidermal growth factor receptor(Human)
Ariad Pharmaceuticals

US Patent
LigandPNGBDBM368429(US10227342, Example 61)
Affinity DataIC50: 100nMAssay Description:A compound's ability in selectively inhibiting EGFR exon 20 insertion mutations can be assessed using Ba/F3 cells, a murine pro-B cell line, whic...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetEpidermal growth factor receptor(Human)
Ariad Pharmaceuticals

US Patent
LigandPNGBDBM368429(US10227342, Example 61)
Affinity DataIC50: 100nMAssay Description:A compound's ability in selectively inhibiting EGFR exon 20 insertion mutations can be assessed using Ba/F3 cells, a murine pro-B cell line, whic...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetEpidermal growth factor receptor [T790M](Human)
Ariad Pharmaceuticals

US Patent
LigandPNGBDBM368428(US10227342, Example 60)
Affinity DataIC50: 100nMAssay Description:A compound's ability in selectively inhibiting EGFR exon 19 deletion and T790M concurrent mutations can be assessed using Ba/F3 cells, a murine p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetEpidermal growth factor receptor [T790M](Human)
Ariad Pharmaceuticals

US Patent
LigandPNGBDBM368426(US10227342, Example 58)
Affinity DataIC50: 100nMAssay Description:A compound's ability in selectively inhibiting EGFR exon 19 deletion and T790M concurrent mutations can be assessed using Ba/F3 cells, a murine p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetEpidermal growth factor receptor(Human)
Ariad Pharmaceuticals

US Patent
LigandPNGBDBM368426(US10227342, Example 58)
Affinity DataIC50: 100nMAssay Description:A compound's ability in selectively inhibiting EGFR exon 20 insertion mutations can be assessed using Ba/F3 cells, a murine pro-B cell line, whic...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetEpidermal growth factor receptor(Human)
Ariad Pharmaceuticals

US Patent
LigandPNGBDBM368426(US10227342, Example 58)
Affinity DataIC50: 100nMAssay Description:A compound's ability in selectively inhibiting EGFR exon 20 insertion mutations can be assessed using Ba/F3 cells, a murine pro-B cell line, whic...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetEpidermal growth factor receptor(Human)
Ariad Pharmaceuticals

US Patent
LigandPNGBDBM368427(US10227342, Example 59)
Affinity DataIC50: 100nMAssay Description:A compound's ability in selectively inhibiting EGFR exon 20 insertion mutations can be assessed using Ba/F3 cells, a murine pro-B cell line, whic...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetEpidermal growth factor receptor(Human)
Ariad Pharmaceuticals

US Patent
LigandPNGBDBM368427(US10227342, Example 59)
Affinity DataIC50: 100nMAssay Description:A compound's ability in selectively inhibiting EGFR exon 20 insertion mutations can be assessed using Ba/F3 cells, a murine pro-B cell line, whic...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetEpidermal growth factor receptor(Human)
Ariad Pharmaceuticals

US Patent
LigandPNGBDBM368426(US10227342, Example 58)
Affinity DataIC50: 100nMAssay Description:A compound's ability in selectively inhibiting Her2 exon 20 YVMA insertion mutations can be assessed using Ba/F3 cells, a murine pro-B cell line,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetEpidermal growth factor receptor [T790M,L858R](Human)
Ariad Pharmaceuticals

US Patent
LigandPNGBDBM368426(US10227342, Example 58)
Affinity DataIC50: 100nMAssay Description:A compound's ability in selectively inhibiting EGFR L858R and T790M concurrent mutations can be assessed using Ba/F3 cells, a murine pro-B cell l...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetEpidermal growth factor receptor(Human)
Ariad Pharmaceuticals

US Patent
LigandPNGBDBM368432(US10227342, Example 64)
Affinity DataIC50: 100nMAssay Description:A compound's ability in selectively inhibiting EGFR exon 20 insertion mutations can be assessed using Ba/F3 cells, a murine pro-B cell line, whic...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetEpidermal growth factor receptor(Human)
Ariad Pharmaceuticals

US Patent
LigandPNGBDBM368432(US10227342, Example 64)
Affinity DataIC50: 100nMAssay Description:A compound's ability in selectively inhibiting EGFR exon 20 insertion mutations can be assessed using Ba/F3 cells, a murine pro-B cell line, whic...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetEpidermal growth factor receptor [T790M](Human)
Ariad Pharmaceuticals

US Patent
LigandPNGBDBM368431(US10227342, Example 63)
Affinity DataIC50: 100nMAssay Description:A compound's ability in selectively inhibiting EGFR exon 19 deletion and T790M concurrent mutations can be assessed using Ba/F3 cells, a murine p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetEpidermal growth factor receptor(Human)
Ariad Pharmaceuticals

US Patent
LigandPNGBDBM368433(US10227342, Example 65)
Affinity DataIC50: 100nMAssay Description:A compound's ability in selectively inhibiting EGFR exon 20 insertion mutations can be assessed using Ba/F3 cells, a murine pro-B cell line, whic...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetEpidermal growth factor receptor(Human)
Ariad Pharmaceuticals

US Patent
LigandPNGBDBM368433(US10227342, Example 65)
Affinity DataIC50: 100nMAssay Description:A compound's ability in selectively inhibiting EGFR exon 20 insertion mutations can be assessed using Ba/F3 cells, a murine pro-B cell line, whic...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetEpidermal growth factor receptor(Human)
Ariad Pharmaceuticals

US Patent
LigandPNGBDBM368432(US10227342, Example 64)
Affinity DataIC50: 100nMAssay Description:A compound's ability in selectively inhibiting Her2 exon 20 YVMA insertion mutations can be assessed using Ba/F3 cells, a murine pro-B cell line,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetEpidermal growth factor receptor [T790M](Human)
Ariad Pharmaceuticals

US Patent
LigandPNGBDBM368432(US10227342, Example 64)
Affinity DataIC50: 100nMAssay Description:A compound's ability in selectively inhibiting EGFR exon 19 deletion and T790M concurrent mutations can be assessed using Ba/F3 cells, a murine p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetEpidermal growth factor receptor(Human)
Ariad Pharmaceuticals

US Patent
LigandPNGBDBM368430(US10227342, Example 62)
Affinity DataIC50: 100nMAssay Description:A compound's ability in selectively inhibiting EGFR exon 20 insertion mutations can be assessed using Ba/F3 cells, a murine pro-B cell line, whic...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetEpidermal growth factor receptor(Human)
Ariad Pharmaceuticals

US Patent
LigandPNGBDBM368430(US10227342, Example 62)
Affinity DataIC50: 100nMAssay Description:A compound's ability in selectively inhibiting EGFR exon 20 insertion mutations can be assessed using Ba/F3 cells, a murine pro-B cell line, whic...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

Displayed 1 to 50 (of 400 total ) | Next | Last >>
Jump to: